RE:RE:RE:RE:USA Inflation Reduction Act (IRA) 2022 Re: Biotech and ChinaAugust 20, 2024 - "Aside from questioning the "trustworthiness" of clinical data generated at these institutions, the lawmakers warned that U.S. biopharmas have run clinical studies with hospitals in Xinjiang, where China has been accused of committing genocide against Uyghur Muslims. “Given the historical suppression and medical discrimination against ethnic minorities in this region, there are significant ethical concerns around conducting clinical trials in the [Xinjiang Uyghur Autonomous Region],” the lawmakers wrote.
Ethics concerns aside, the group from the House committee further argued that collaborative research with China’s military puts U.S. intellectual property at risk.
In their review of U.S. clinical trials that included sites at China’s military hospitals, the lawmakers specifically homed in on an ongoing trial of Eli Lilly’s Alzheimer’s disease drug donanemab—which was recently approved in the U.S. as Kisunla—and a former study of Pfizer’s Inlyta in liver cancer.
The letter states that Lilly’s trial is being run at the PLA’s General Hospital and Medical School and the military’s Air Force Medical University. The study on Pfizer’s medicine was conducted with a hospital under the PLA’s Academy of Military Medical Sciences (AMMS), according to the lawmakers' letter."
https://www.fiercepharma.com/pharma/amid-biosecure-brouhaha-house-committee-urges-fda-investigate-clinical-trials-run-tandem